Louvain-La-Neuve, Belgium, February 26, 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today provides a trading update ahead of the Company’s full-year results on March 21, 2019.

As previously announced, IBA signed seven Proteus®ONE* contracts in 2018, three of which have started to generate revenues in 2018. The four outstanding Proton Therapy contracts will not be recognized in the 2018 numbers anymore. The year also saw double-digit growth of Proton Therapy service revenues, a record order intake in the Other Accelerators division and good performance of the Dosimetry segment.

Over the year, IBA has made significant progress towards sustained profitability through a company-wide focus on operating expenses and cost-efficiency. These initiatives have resulted in an operating expense reduction of more than EUR 15 million in 2018.

Concurrently, with the strength of the elements mentioned above, the Company moved into profit at both a REBIT and Net Income level in the second half compared with the first half of 2018.

For the full year, IBA confirms that it will meet its 2018 full-year guidance of positive REBIT. At the net result level, the Company now expects to post a single digit (in EUR million) loss, a significant improvement on the net loss of EUR 39.2 million a year earlier.

Olivier Legrain, Chief Executive Officer of IBA commented: “IBA has made a strong recovery in 2018, reinforcing our position as global leader in the proton therapy market. Although current market conditions remain challenging and the signing and financing of new contracts is hard to forecast, we are confident in the longer-term prospects for the proton therapy market. We begin 2019 with a clear focus on driving growth through continued product innovation that meets the needs of customers and patients, underpinned by tight control of our costs to achieve sustained profitability.”



About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com


* Proteus®ONE is the brand name of Proteus®235


For further information, please contact:

Soumya Chandramouli
Chief Financial Officer
+32 10 475 890

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890


For media and investor enquiries:

Consilium Strategic Communications
Matthew Neal, Angela Gray, Lizzie Seeley
+44 (0) 20 3709 5700